EP3601565A4 - Mir-92 inhibitors for treatment of heart failure - Google Patents

Mir-92 inhibitors for treatment of heart failure Download PDF

Info

Publication number
EP3601565A4
EP3601565A4 EP18777343.7A EP18777343A EP3601565A4 EP 3601565 A4 EP3601565 A4 EP 3601565A4 EP 18777343 A EP18777343 A EP 18777343A EP 3601565 A4 EP3601565 A4 EP 3601565A4
Authority
EP
European Patent Office
Prior art keywords
mir
inhibitors
treatment
heart failure
heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18777343.7A
Other languages
German (de)
French (fr)
Other versions
EP3601565A1 (en
Inventor
Rabea Hinkel
Christian Kupatt
Stefanie Dimmeler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viridian Therapeutics Inc
Original Assignee
Miragen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miragen Therapeutics Inc filed Critical Miragen Therapeutics Inc
Publication of EP3601565A1 publication Critical patent/EP3601565A1/en
Publication of EP3601565A4 publication Critical patent/EP3601565A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP18777343.7A 2017-03-25 2018-03-23 Mir-92 inhibitors for treatment of heart failure Withdrawn EP3601565A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762476780P 2017-03-25 2017-03-25
US201762477385P 2017-03-27 2017-03-27
PCT/US2018/024167 WO2018183127A1 (en) 2017-03-25 2018-03-23 Mir-92 inhibitors for treatment of heart failure

Publications (2)

Publication Number Publication Date
EP3601565A1 EP3601565A1 (en) 2020-02-05
EP3601565A4 true EP3601565A4 (en) 2021-01-06

Family

ID=63676655

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18777343.7A Withdrawn EP3601565A4 (en) 2017-03-25 2018-03-23 Mir-92 inhibitors for treatment of heart failure

Country Status (2)

Country Link
EP (1) EP3601565A4 (en)
WO (1) WO2018183127A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201791644A1 (en) 2015-01-20 2018-01-31 Мираджен Терапьютикс, Инк. MIR-92 INHIBITORS AND THEIR APPLICATION
EP4269586A1 (en) 2022-04-29 2023-11-01 Johann-Wolfgang-Goethe-Universität Frankfurt am Main Targeting micro rna for treatment of heart failure with preserved ejection fraction (hfpef)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014115103A1 (en) * 2013-01-24 2014-07-31 Pierre Fabre Medicament S.A.S. Composition comprising an encapsulated antagomir

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110086348A1 (en) * 2009-02-19 2011-04-14 The Cleveland Clinic Foundation Method for assessing heart disease
NZ596971A (en) * 2009-05-20 2013-12-20 Univ Texas Identification of micro-rnas involved in post-myocardial infarction remodeling and heart failure
JP6208228B2 (en) * 2012-06-21 2017-10-04 ミラゲン セラピューティクス， インコーポレイテッド Oligonucleotide-based inhibitors containing locked nucleic acid motifs
US20160251720A1 (en) * 2013-11-01 2016-09-01 The Trustees Of Columbia University In The City New York MicroRNA PROFILES IN HEART FAILURE: METHODS AND SYSTEMS FOR DETECTION AND USE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014115103A1 (en) * 2013-01-24 2014-07-31 Pierre Fabre Medicament S.A.S. Composition comprising an encapsulated antagomir

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FUJITA MASANORI ET AL: "Inhibition of MicroRNA-92a Enhances Angiogenesis and Cardiomyocyte Regeneration Through Integrin a5-Dependent Accumulation of Stem Cells Into the Infarcted Myocardium", CIRCULATION, vol. 124, no. 21, Suppl. S, November 2011 (2011-11-01), & SCIENTIFIC SESSIONS OF THE AMERICAN-HEART-ASSOCIATION/RESUSCITATION SCIENCE SYMPOSIUM; ORLANDO, FL, USA; NOVEMBER 12 -16, 2011, pages A12590, XP002800953 *
R. HINKEL ET AL: "Inhibition of MicroRNA-92a Protects Against Ischemia/Reperfusion Injury in a Large-Animal Model", CIRCULATION, vol. 128, no. 10, 3 September 2013 (2013-09-03), US, pages 1066 - 1075, XP055375248, ISSN: 0009-7322, DOI: 10.1161/CIRCULATIONAHA.113.001904 *
See also references of WO2018183127A1 *
XINYU LIU ET AL: "Role of microRNAs in the pathogenesis of diabetic cardiomyopathy", BIOMEDICAL REPORTS MAY 2014 SPANDIDOS PUBLICATIONS GBR, vol. 6, no. 2, 12 January 2017 (2017-01-12), Greece, pages 140 - 145, XP055749498, ISSN: 2049-9434, DOI: 10.3892/br.2017.841 *

Also Published As

Publication number Publication date
EP3601565A1 (en) 2020-02-05
WO2018183127A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
EP3313325A4 (en) Implantable scaffolds for treatment of sinusitis
EP3426250A4 (en) Methods of treatment
EP3256218A4 (en) Kdm1a inhibitors for the treatment of disease
EP3261713A4 (en) Blood pump for treatment of bradycardia
EP3204009A4 (en) Heparan sulfate biosynthesis inhibitors for the treatment of diseases
EP3157534A4 (en) Acetylcholinesterase inhibitors for treatment of dermatological conditions
PT3297628T (en) Calcineurin inhibitors of the setron family for the treatment of hearing loss
EP3684342A4 (en) Method of treatment
EP3285767B8 (en) Treatment of pain
EP3490545A4 (en) Methods of medical treatment with sur1-trpm4 channel inhibitors
EP3256137A4 (en) Method of treating heart failure
IL250662A0 (en) Tissue protecting devices for treatment of congestive heart failure and other conditions
EP3612133A4 (en) Implantable scaffolds for treatment of sinusitis
EP3601565A4 (en) Mir-92 inhibitors for treatment of heart failure
EP3490547A4 (en) Method of treatment
EP3259346A4 (en) P63 inactivation for the treatment of heart failure
EP3481399A4 (en) Methods for treatment of heart failure
IL275273A (en) Improved compound for treatment of heart failure
EP3271017A4 (en) Treatment of skin conditions
EP3612178A4 (en) Vasodilators for treatment of heart failure
EP3890780A4 (en) Method of treatment
EP3727376A4 (en) Methods of treatment of hypertrigl yceridemia
PT3724336T (en) Improved compound for treatment of heart failure
AU2017904855A0 (en) Method of treatment
AU2017903829A0 (en) Method of treatment

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191023

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20201207

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/113 20100101ALI20201130BHEP

Ipc: C12N 15/11 20060101AFI20201130BHEP

Ipc: A61K 31/712 20060101ALI20201130BHEP

Ipc: A61P 9/10 20060101ALN20201130BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210722